Call for Intentions to Cooperate on NORTHLAND's Innovative Drug Donaperminogene Seltoplasmid Ingection (Not Yet Approved)
Product Information (Under Registration and Filing)

Project Name: Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection
Generic Name: Donaperminogene Seltoplasmid Injection
Specification: 2 mg/1 ml/vial
Registration Category: Class 1 Therapeutic Biological Products
Target population: This product is intended for individuals suffering from limb ulcers caused by severe lower-limb ischemia, including conditions such as lower-limb arterial sclerosis and occlusion, thrombo-obliterative vasculitis, and diabetic lower-limb ischemia.
Mechanism of action: By injecting this product into the muscle tissue at the ischemic site, the expression and secretion of HGF in striated muscle cells specifically stimulate the proliferation of endothelial cells and the migration of vascular smooth muscle cells at the ischemic site, thereby promoting angiogenesis and the establishment of collateral circulation.

Cooperation Negotiation Terms

We sincerely invite companies with the following characteristics to discuss potential collaborations:
1. Pharmaceutical distribution enterprises with corporate legal status that comply with GSP standards.
2. Pharmaceutical sales, promotion, and other business activities comply with regulatory requirements.
3. Possess a professional clinical academic promotion team with experience in post-marketing promotion of innovative drugs, as well as an expert network and market resources in vascular surgery or related fields.
4. Possesses a mature and highly efficient in-house team in the hospital market of the target province/city, as well as capabilities for bidding and hospital access following the launch of innovative drugs; also has expertise in handling government affairs.
5. Possesses deep market insights and strategic planning capabilities.

Contact Information

We welcome inquiries from high-quality partners across the country and look forward to in-depth exchanges and discussions with you.
Contact: Mr. Pan Jie
Landline: 021-52927896 | Phone: 15167265535
Email: panjie@northland-bio.com

This product has not yet been approved for marketing by the National Medical Products Administration (NMPA) and is currently in the application stage for market approval. The information provided above is intended solely for the purpose of soliciting expressions of interest in cooperation and facilitating communication; it does not, under any circumstances, constitute any form of pharmaceutical advertising, sales commitment, or medication guidance.